Mode
Text Size
Log in / Sign up
Phase 4 N=10 Randomized Double-blind Treatment

Effects of Viagra on Heart Function in Patients With Heart Failure

Heart Failure · Left Ventricular Dysfunction

Enrolled (actual)
10
Serious AEs
0.0%
Results posted
Jun 2014
Primary outcome: Primary: Reduction of the Left Ventricular Filling Pressure in Association With Administration of Sildenafil — 16.7; 16.4 E/e' ratio

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
sildenafil (Drug); Placebo (Other)
Age
Adult, Older Adult · 25+ yrs
Sex
All
Sponsor
MetroHealth Medical Center
Primary completion
Sep 2009

Outcome Measures

OutcomeResultp-value
PRIMARY
Reduction of the Left Ventricular Filling Pressure in Association With Administration of Sildenafil
16.7; 16.4
SECONDARY
The Distance Walked During the 6-minute Walk Test 1 hr After the Oral Administration of Sildenafil 50 mg.
210; 219

Summary

Sildenafil (Viagra) is known to reduce pulmonary hypertension. Heart failure patients also have pulmonary hypertension and several recent reports have shown that sildenafil leads to an improvement in their exercise capacity. In these studies sildenafil caused a reduction in the pulmonary and systemic vascular resistances, improved pulmonary gas diffusion and perhaps increased cardiac output. It is uncertain if left ventricular filling pressures are reduced and whether there is improvement in left ventricular relaxation. The investigators hypothesize that in heart failure patients the improvement in exercise capacity associated with sildenafil is related to a significant reduction in left ventricular filling pressures. The investigators propose to study 20 patients with stable but moderately symptomatic heart failure. The study design is a randomized cross-over trial of the administration of a single dose of sildenafil 50 mg or a matching placebo. Exercise capacity will be determined before and after the oral administration of sildenafil 50 mg or placebo. Left ventricular filling pressures will be assessed by Doppler echocardiography and the serum level of B-type natriuretic peptide (BNP is known to increase with higher left ventricular filling pressures). After an initial echocardiogram and performing a 6 minute walk test, the patient will then be given either sildenafil or a matching placebo in a randomized double-blind fashion. One hr later a blood sample for serum BNP, the echocardiogram and the 6 minute walk test will be repeated.

Eligibility Criteria

Inclusion Criteria

  • Adults with Class III congestive heart failure and impaired left ventricular systolic function.
  • A prior BNP level ≥ 200 pg/mL.
  • Previously documented systolic pulmonary artery pressure >40 mmHg.
  • Clinically stable for a minimum of 6 weeks.
  • Able to give informed consent,

Exclusion Criteria

  • Unable to give informed consent.
  • Currently taking nitrates.
  • A HF exacerbation within the past 6 weeks.
  • Co-morbid conditions that could limit their walking.
  • Have a resting systolic blood pressure < 110 mmHg
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00781508). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search